Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma

NCT01557114 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
19
Enrollment
OTHER
Sponsor class

Stopped New compounds available in the indication (nivolumab/pembrolizumab), toxicity of ipilimumab

Conditions

Interventions

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris